Ishikawa Sho, Maruyama Takafumi, Murayama Koichiro, Shinoda Kei
Department of Ophthalmology, Saitama Medical University, Saitama 350-0495, Japan.
Tsuruse Murayama Eye Clinic, Saitama 354-0021, Japan.
J Clin Med. 2025 Apr 18;14(8):2790. doi: 10.3390/jcm14082790.
Long-acting (extended) diquafosol ophthalmic solution 3% (DQSLX) is administered less frequently (three times daily) than diquafosol ophthalmic solution (DQS) (six times daily). However, some patients do not prefer DQSLX because of perceived stickiness. We investigated the subjective and objective characteristics of patients with dry eye who switched from using DQSLX to DQS. We retrospectively enrolled 51 patients (11 men and 40 women) whose eye drop prescription was changed from DQSLX to DQS between June 2024 and September 2024. Subjective symptoms, tear break-up time, and fluorescein-staining scores were evaluated from baseline to 4 weeks after DQS use. We asked the participants to choose between DQS and DQSLX 4 weeks after using DQS. In total, 51 eyes of 51 patients (11 men and 40 women; mean age: 68.2 ± 14.7 years) were enrolled. The DQS group showed significant worsening of the subjective symptoms, tear break-up time, and fluorescein staining scores (20.8 ± 22.5, 5.2 ± 3.4, and 1.6 ± 2.0, respectively) relative to the baseline (15.9 ± 18.7, 6.3 ± 3.2, and 0.7 ± 1.4, respectively) ( = 0.003, < 0.001, and <0.001, respectively). Eleven (21.6%) patients expressed their preference for continuing DQS because of the good sensation of the eye drops. An analysis of the group that preferred the DQS ophthalmic solution revealed no significant changes in subjective symptoms or fluorescein staining scores after DQS treatment. DQSLX improved the subjective symptoms and objective findings of patients with dry eye relative to DQS.
3%长效（延长型）地夸磷索滴眼液（DQSLX）的给药频率（每日三次）低于地夸磷索滴眼液（DQS）（每日六次）。然而，一些患者因感觉黏稠而不喜欢DQSLX。我们调查了从使用DQSLX改用DQS的干眼症患者的主观和客观特征。我们回顾性纳入了2024年6月至2024年9月期间滴眼液处方从DQSLX改为DQS的51例患者（11例男性和40例女性）。从基线到使用DQS后4周，评估主观症状、泪膜破裂时间和荧光素染色评分。在使用DQS 4周后，我们让参与者在DQS和DQSLX之间进行选择。总共纳入了51例患者的51只眼（11例男性和40例女性；平均年龄：68.2±14.7岁）。与基线相比，DQS组的主观症状、泪膜破裂时间和荧光素染色评分显著恶化（分别为20.8±22.5、5.2±3.4和1.6±2.0）（分别为0.003、<0.001和<0.001）（基线分别为15.9±18.7、6.3±3.2和0.7±1.4）。11例（21.6%）患者表示因滴眼液感觉良好而倾向于继续使用DQS。对倾向于使用DQS滴眼液的组进行分析发现，DQS治疗后主观症状或荧光素染色评分无显著变化。相对于DQS，DQSLX改善了干眼症患者的主观症状和客观检查结果。
